ASP Isotopes (NASDAQ:ASPI) COO Robert Ainscow Sells 8,438 Shares of Stock

ASP Isotopes Inc. (NASDAQ:ASPI) COO Robert Ainscow sold 8,438 shares of ASP Isotopes stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $4.29, for a total value of $36,199.02. Following the completion of the sale, the chief operating officer directly owned 2,248,441 shares in the company, valued at approximately $9,645,811.89. This represents a 0.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Robert Ainscow also recently made the following trade(s):

• On Wednesday, September 2nd, Robert Ainscow sold 25,000 shares of ASP Isotopes stock. The stock was sold at an average price of $3.90, for a total value of $97,500.00.

ASP Isotopes Stock Performance

Shares of NASDAQ ASPI opened at $3.31 on Friday. The stock has a 50 day moving average price of $4.16 and a 200 day moving average price of $5.15. ASP Isotopes Inc. has a 52 week low of $3.30 and a 52 week high of $14.49. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.85 and a current ratio of 3.87. The stock has a market capitalization of $507.46 million, a PE ratio of -2.51 and a beta of 3.59.

ASP Isotopes (NASDAQ:ASPI) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.11). ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%.The company had revenue of $5.12 million for the quarter, compared to analyst estimates of $4.47 million.

Institutional Trading of ASP Isotopes

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of ASP Isotopes during the 2nd quarter worth approximately $57,331,000. Encompass Capital Advisors LLC acquired a new stake in ASP Isotopes during the 1st quarter valued at $30,551,000. Alyeska Investment Group L.P. lifted its holdings in ASP Isotopes by 73.4% during the 4th quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company’s stock valued at $26,191,000 after purchasing an additional 2,072,851 shares during the last quarter. AWM Investment Company Inc. bought a new position in ASP Isotopes during the second quarter worth $9,837,000. Finally, UBS Group AG boosted its position in ASP Isotopes by 150.3% during the fourth quarter. UBS Group AG now owns 2,406,457 shares of the company’s stock worth $12,875,000 after purchasing an additional 1,445,165 shares during the period. 16.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ASPI. Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of ASP Isotopes from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $13.00.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.